Search

Your search keyword '"Shinohara, Nobuo"' showing total 2,016 results
Start Over Author "Shinohara, Nobuo"
2,016 results on '"Shinohara, Nobuo"'

2. The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy

Author

Numakura, Kazuyuki, Sekine, Yuya, Osawa, Takahiro, Naito, Sei, Tokairin, Ojiro, Muto, Yumina, Sobu, Ryuta, Kobayashi, Mizuki, Sasagawa, Hajime, Yamamoto, Ryohei, Nara, Taketoshi, Saito, Mitsuru, Narita, Shintaro, Akashi, Hideo, Tsuchiya, Norihiko, Shinohara, Nobuo, and Habuchi, Tomonori

Published
2024
Full Text
View/download PDF

13. Validation and motion analyses of laparoscopic radical nephrectomy with Thiel-embalmed cadavers

Author

Yan, Lingbo, Ebina, Koki, Abe, Takashige, Kon, Masafumi, Higuchi, Madoka, Hotta, Kiyohiko, Furumido, Jun, Iwahara, Naoya, Komizunai, Shunsuke, Tsujita, Teppei, Sase, Kazuya, Chen, Xiaoshuai, Kurashima, Yo, Kikuchi, Hiroshi, Miyata, Haruka, Matsumoto, Ryuji, Osawa, Takahiro, Murai, Sachiyo, Shichinohe, Toshiaki, Murakami, Soichi, Senoo, Taku, Watanabe, Masahiko, Konno, Atsushi, and Shinohara, Nobuo

Published
2024
Full Text
View/download PDF

16. Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma

Author

Yamada, Shuhei, Miyata, Haruka, Isono, Makoto, Hori, Kanta, Yanagawa, Junko, Murai, Aiko, Minowa, Tomoyuki, Mizue, Yuka, Sasaki, Kenta, Murata, Kenji, Tokita, Serina, Nakatsugawa, Munehide, Iwabuchi, Sadahiro, Hashimoto, Shinichi, Kubo, Terufumi, Kanaseki, Takayuki, Tsukahara, Tomohide, Abe, Takashige, Shinohara, Nobuo, Hirohashi, Yoshihiko, and Torigoe, Toshihiko

Published
2023
Full Text
View/download PDF

17. Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial

Author

Shiota, Masaki, Miyake, Hideaki, Takahashi, Masayuki, Oya, Mototsugu, Tsuchiya, Norihiko, Masumori, Naoya, Matsuyama, Hideyasu, Obara, Wataru, Shinohara, Nobuo, Fujimoto, Kiyohide, Nozawa, Masahiro, Ohba, Kojiro, Ohyama, Chikara, Hashine, Katsuyoshi, Akamatsu, Shusuke, Kamba, Tomomi, Mita, Koji, Gotoh, Momokazu, Tatarano, Shuichi, Fujisawa, Masato, Tomita, Yoshihiko, Mukai, Shoichiro, Ito, Keiichi, Tanegashima, Tokiyoshi, Tokunaga, Shoji, and Eto, Masatoshi

Published
2023
Full Text
View/download PDF

20. Objective evaluation of laparoscopic surgical skills in wet lab training based on motion analysis and machine learning

Author

Ebina, Koki, Abe, Takashige, Hotta, Kiyohiko, Higuchi, Madoka, Furumido, Jun, Iwahara, Naoya, Kon, Masafumi, Miyaji, Kou, Shibuya, Sayaka, Lingbo, Yan, Komizunai, Shunsuke, Kurashima, Yo, Kikuchi, Hiroshi, Matsumoto, Ryuji, Osawa, Takahiro, Murai, Sachiyo, Tsujita, Teppei, Sase, Kazuya, Chen, Xiaoshuai, Konno, Atsushi, and Shinohara, Nobuo

Published
2022
Full Text
View/download PDF

22. MP01-03 CURRENT TREATMENT PATTERNS AND OUTCOMES OF 109 PATIENTS WITH SEX CORD STROMAL TUMORS IN JAPAN: A MULTI-INSTITUTIONAL STUDY

Author

Abe, Takashige, primary, Miyai, Kosuke, additional, Tsuzuki, Toyonori, additional, Hashine, Katsuyoshi, additional, Yamashita, Shinichi, additional, Kawahara, Takashi, additional, Nishiya, Naotaka, additional, Kitamura, Hiroshi, additional, Nishiyama, Hiroyuki, additional, Miyata, Haruka, additional, Matusmoto, Ryuji, additional, Osawa, Takahiro, additional, Murai, Sachiyo, additional, and Shinohara, Nobuo, additional

Published
2024
Full Text
View/download PDF

26. Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2

Author

Tozawa, Akiko, Kimura, Fuminori, Takai, Yasushi, Nakajima, Takeshi, Ushijima, Kimio, Kobayashi, Hiroaki, Satoh, Toyomi, Harada, Miyuki, Sugimoto, Kohei, Saji, Shigehira, Shimizu, Chikako, Akiyama, Kyoko, Bando, Hiroko, Kuwahara, Akira, Furui, Tatsuro, Okada, Hiroshi, Kawai, Koji, Shinohara, Nobuo, Nagao, Koichi, Kitajima, Michio, Suenobu, Souichi, Soejima, Toshinori, Miyachi, Mitsuru, Miyoshi, Yoko, Yoneda, Akihiro, Horie, Akihito, Ishida, Yasushi, Usui, Noriko, Kanda, Yoshinobu, Fujii, Nobuharu, Endo, Makoto, Nakayama, Robert, Hoshi, Manabu, Yonemoto, Tsukasa, Kiyotani, Chikako, Okita, Natsuko, Baba, Eishi, Muto, Manabu, Kikuchi, Iwaho, Morishige, Ken-ichirou, Tsugawa, Koichiro, Nishiyama, Hiroyuki, Hosoi, Hajime, Tanimoto, Mitsune, Kawai, Akira, Sugiyama, Kazuhiko, Boku, Narikazu, Yonemura, Masato, Hayashi, Naoko, Aoki, Daisuke, Suzuki, Nao, and Osuga, Yutaka

Published
2022
Full Text
View/download PDF

27. Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 1

Author

Harada, Miyuki, Kimura, Fuminori, Takai, Yasushi, Nakajima, Takeshi, Ushijima, Kimio, Kobayashi, Hiroaki, Satoh, Toyomi, Tozawa, Akiko, Sugimoto, Kohei, Saji, Shigehira, Shimizu, Chikako, Akiyama, Kyoko, Bando, Hiroko, Kuwahara, Akira, Furui, Tatsuro, Okada, Hiroshi, Kawai, Koji, Shinohara, Nobuo, Nagao, Koichi, Kitajima, Michio, Suenobu, Souichi, Soejima, Toshinori, Miyachi, Mitsuru, Miyoshi, Yoko, Yoneda, Akihiro, Horie, Akihito, Ishida, Yasushi, Usui, Noriko, Kanda, Yoshinobu, Fujii, Nobuharu, Endo, Makoto, Nakayama, Robert, Hoshi, Manabu, Yonemoto, Tsukasa, Kiyotani, Chikako, Okita, Natsuko, Baba, Eishi, Muto, Manabu, Kikuchi, Iwaho, Morishige, Ken-ichirou, Tsugawa, Koichiro, Nishiyama, Hiroyuki, Hosoi, Hajime, Tanimoto, Mitsune, Kawai, Akira, Sugiyama, Kazuhiko, Boku, Narikazu, Yonemura, Masato, Hayashi, Naoko, Aoki, Daisuke, Osuga, Yutaka, and Suzuki, Nao

Published
2022
Full Text
View/download PDF

31. IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation

Author

Kato, Taigo, Matsubara, Nobuaki, Shiota, Masaki, Eto, Masatoshi, Osawa, Takahiro, Abe, Takashige, Shinohara, Nobuo, Yasumizu, Yota, Tanaka, Nobuyuki, Oya, Mototsugu, Nishimoto, Koshiro, Hayashi, Takuji, Nakayama, Masashi, Kojima, Takahiro, Namikawa, Kenjiro, Fujisawa, Takao, Okano, Susumu, Hida, Eisuke, Nakamura, Yoshiaki, Bando, Hideaki, Yoshino, Takayuki, and Nonomura, Norio

Published
2022
Full Text
View/download PDF

32. Validation of the Japanese version of the Body Image Scale for bladder cancer patients

Author

Sato, Miho, Osawa, Takahiro, Abe, Takashige, Honda, Michitaka, Higuchi, Madoka, Yamada, Shuhei, Furumido, Jun, Kikuchi, Hiroshi, Matsumoto, Ryuji, Sato, Yasuyuki, Sasaki, Yoshihiro, Harabayashi, Toru, Maruyama, Satoru, Takada, Norikata, Minami, Keita, Tanaka, Hiroshi, Morita, Ken, Kashiwagi, Akira, Murai, Sachiyo, Ito, Yoichi M., Ogasawara, Katsuhiko, and Shinohara, Nobuo

Published
2022
Full Text
View/download PDF

33. Association of exposure to prenatal perfluoroalkyl substances and estrogen receptor 1 polymorphisms with the second to fourth digit ratio in school-aged children: The Hokkaido study

Author

Nishimura, Yoko, Moriya, Kimihiko, Kobayashi, Sumitaka, Ikeda- Araki, Atsuko, Sata, Fumihiro, Mitsui, Takahiko, Itoh, Sachiko, Miyashita, Chihiro, Cho, Kazutoshi, Kon, Masafumi, Nakamura, Michiko, Kitta, Takeya, Murai, Sachiyo, Kishi, Reiko, and Shinohara, Nobuo

Published
2022
Full Text
View/download PDF

34. Effect of Simulation-based Training on Surgical Proficiency and Patient Outcomes: A Randomised Controlled Clinical and Educational Trial

Author

Baig, Umair, Aya, Haleema, Husnain Iqbal, Mohammed, Kum, Francesca, Bultitude, Matthew, Glass, Jonathan, Khan, Azhar, Makanjuola, Jonathan, McCabe, John E., Samsuddin, Azi, McIlhenny, Craig, Brewin, James, Kulkarni, Shashank, Khwaja, Sikandar, Islam, Waliul, Marsh, Howard, Bhat, Taher, Thomas, Benjamin, Cutress, Mark, Housami, Fadi, Nedas, Timothy, Bates, Timothy, Mukherjee, Rono, Graham, Stuart, Bordenave, Matthieu, Coker, Charles, Ahmed, Shwan, Symes, Andrew, Calvert, Robert, Lynch, Ciaran, Long, Ronan, Patterson, Jacob M., Rukin, Nicholas J., Khan, Shahid A., Dasgupta, Ranan, Brown, Stephen, Grey, Ben, Mahmalji, Waseem, Lam, Wayne, Scheitlin, Walter, Saelzler, Norbert, Fiedler, Marcel, Ishikawa, Shuhei, Sasaki, Yoshihiro, Sazawa, Ataru, Shinno, Yuichiro, Mochizuki, Tango, Peter Jessen, Jan, Steiner, Roland, Wendt-Nordahl, Gunnar, Atassi, Nabil, Kohns, Heiko, Cox, Ashley, Rendon, Ricardo, Lawen, Joseph, Bailly, Greg, Marsh, Trevor, Aydın, Abdullatif, Ahmed, Kamran, Abe, Takashige, Raison, Nicholas, Van Hemelrijck, Mieke, Garmo, Hans, Ahmed, Hashim U., Mukhtar, Furhan, Al-Jabir, Ahmed, Brunckhorst, Oliver, Shinohara, Nobuo, Zhu, Wei, Zeng, Guohua, Sfakianos, John P., Gupta, Mantu, Tewari, Ashutosh, Gözen, Ali Serdar, Rassweiler, Jens, Skolarikos, Andreas, Kunit, Thomas, Knoll, Thomas, Moltzahn, Felix, Thalmann, George N., Lantz Powers, Andrea G., Chew, Ben H., Sarica, Kemal, Shamim Khan, Muhammad, and Dasgupta, Prokar

Published
2022
Full Text
View/download PDF

35. Predictive Factors of Early 18F-Fluorodeoxyglucose-Positron Emission Tomography Response to [131I] Metaiodobenzylguanidine Treatment for Unresectable or Metastatic Pheochromocytomas and Paragangliomas.

Author

Takenaka, Junki, Watanabe, Shiro, Abe, Takashige, Tsuchikawa, Takahiro, Takeuchi, Satoshi, Hirata, Kenji, Kimura, Rina, Wakabayashi, Naoto, Shinohara, Nobuo, and Kudo, Kohsuke

Subjects
LOGISTIC regression analysis, NEUROENDOCRINE tumors, PROGNOSIS, OVERALL survival, TREATMENT effectiveness
Abstract

Introduction: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours that produce catecholamines. [131I] metaiodobenzylguanidine (MIBG)-avid unresectable or metastatic PPGLs are treated with [131I] MIBG radionuclide therapy. A high metabolic tumour volume (MTV) and total lesion glycolysis (TLG) can be poor prognostic factors. Therefore, we evaluated the metabolic responses to [131I] MIBG therapy with respect to other clinical factors. Methods: A retrospective study was performed on a series of 20 patients who underwent FDG-PET before and after [131I] MIBG therapy. We administered a single dose comprising 5.5 GBq of [131I] MIBG (usually three times; for some cases, the number was increased or decreased considering treatment efficacy and side effects). Semi-quantitative parameters (SUVmax, MTV, and TLG) were calculated using the liver SUV (mean + 3 × standard deviation) as a threshold on Metavol software. The semi-quantitative FDG-PET parameters for determining response were complete response (CR), partial remission (PR), stable disease (SD), and progressive disease (PD). We divided our study participants into the PD and non-PD groups (i.e., SD + PR + CR) and compared the overall survival (OS) between the two groups. Subsequently, we evaluated the relationships between metabolic response and age, sex, tumour type, metastatic site, chemotherapy or external radiation history, and 24-h urine catecholamine levels by univariate logistic regression analyses. Results: Both MTV-based and TLG-based criteria for PD versus non-PD were significant prognostic factors (p = 0.014). However, treatment response as evaluated based on the SUVmax was not a significant predictor. Higher urinary dopamine levels were associated with poor metabolic response as assessed by MTV and TLG (OR 1.002, p = 0.029). The other clinical parameters were non-significant. Conclusion: Poor metabolic response (measured with MTV and TLG) to [131I] MIBG therapy in unresectable or metastatic PPGLs was related to shorter OS. The poor metabolic response can be predicted using the urinary dopamine level. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Physiotherapy for continence and muscle function in prostatectomy: a randomised controlled trial.

Author

Ouchi, Mifuka, Kitta, Takeya, Chiba, Hiroki, Higuchi, Madoka, Abe‐Takahashi, Yui, Togo, Mio, Kusakabe, Naohisa, Murai, Sachiyo, Kikuchi, Hiroshi, Matsumoto, Ryuji, Osawa, Takahiro, Abe, Takashige, and Shinohara, Nobuo

Subjects
KEGEL exercises, MUSCLE contraction, PELVIC floor, RADICAL prostatectomy, RANDOMIZED controlled trials, RETROPUBIC prostatectomy
Abstract

Objective: To assess the effectiveness of pre‐ and postoperative supervised pelvic floor muscle training (PFMT) on the recovery of continence and pelvic floor muscle (PFM) function after robot‐assisted laparoscopic radical prostatectomy (RARP). Patients and Methods: We carried out a single‐blind randomised controlled trial involving 54 male patients scheduled to undergo RARP. The intervention group started supervised PFMT 2 months before RARP and continued for 12 months after surgery with a physiotherapist. The control group was given verbal instructions, a brochure about PFMT, and lifestyle advice. The primary outcome was 24‐h pad weight (g) at 3 months after RARP. The secondary outcomes were continence status (assessed by pad use), PFM function, and the Expanded Prostate Cancer Index Composite (EPIC) score. Results: Patients who participated in supervised PFMT showed significantly improved postoperative urinary incontinence (UI) compared with the control group (5.0 [0.0–908.0] g vs 21.0 [0.0–750.0] g; effect size: 0.34, P = 0.022) at 3 months after RARP based on 24‐h pad weight. A significant improvement was seen in the intervention compared with the control group (65.2% continence [no pad use] vs 31.6% continence, respectively) at 12 months after surgery (effect size: 0.34, P = 0.030). Peak pressure during a maximum voluntary contraction was higher in the intervention group immediately after catheter removal and at 6 months, and a longer duration of sustained contraction was found in the intervention group compared with the control group. We were unable to demonstrate a difference between groups in EPIC scores. Conclusion: Supervised PFMT can improve postoperative UI and PFM function after RARP. Further studies are needed to confirm whether intra‐anal pressure reflects PFM function and affects continence status in UI in men who have undergone RARP. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Normalization of impaired glucose tolerance after kidney transplantation is associated with improved β-cell function.

Author

Miyamoto, Maiko, Nakamura, Akinobu, Miya, Aika, Nomoto, Hiroshi, Kameda, Hiraku, Cho, Kyu Yong, Iwahara, Naoya, Hotta, Kiyohiko, Shinohara, Nobuo, and Atsumi, Tatsuya

Subjects
KIDNEY transplantation, BLOOD sugar, GLUCOSE, GLUCOSE tolerance tests, CREATININE, INSULIN sensitivity, BRAIN death
Abstract

Our previous study revealed that over 50% of recipients with pretransplant impaired glucose tolerance (IGT) improved to normal glucose tolerance after kidney transplantation. However, the mechanism is unclear. We aimed to investigate whether the changes in glucose tolerance are associated with β-cell function and insulin resistance in Japanese kidney transplant recipients with pretransplant IGT. Of the 265 recipients who received kidney transplantation, 54 with pretransplant IGT were included. We divided the recipients into improvement and nonimprovement groups according to the change in the area under the curve for glucose obtained from the oral glucose tolerance test (OGTT). β-Cell function was estimated by the insulin secretion sensitivity index-2 (ISSI-2) and the disposition index (DI). Insulin resistance was estimated by the Matsuda index (MI) and the homeostasis model assessment of insulin resistance (HOMA-IR). ISSI-2 and DI increased significantly after transplantation in the improved group (P < 0.01, P < 0.05, respectively), but not in the nonimproved group. ΔISSI-2 and ΔDI were significantly and positively associated with pretransplant 60-min OGTT plasma glucose levels (both P < 0.01). There were no differences in MI or HOMA-IR between these two groups after transplantation. In recipients not on pretransplant dialysis, a significant negative association was found between Δblood urea nitrogen (BUN) and ΔDI (correlation coefficient = −0.48, P < 0.05). In pretransplant IGT recipients, improvements in glucose tolerance after kidney transplantation were linked to improvements in β-cell function. The higher the 60-min OGTT plasma glucose level, the greater the improvement in posttransplant β-cell function. Improvements in BUN after transplantation were associated with improvements in β-cell function. NEW & NOTEWORTHY: In recipients with pretransplant impaired glucose tolerance, improvements in glucose tolerance after kidney transplantation were associated with improvements in β-cell function. The higher the pretransplant 60-min OGTT plasma glucose level, the greater the improvement in posttransplant β-cell function. Although glucose tolerance is known to be impaired after transplantation, the present study focused on the reason for the improvement in glucose tolerance rather than the development of posttransplantation diabetes mellitus. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Surgical Skill Analysis Based on the Way of Grasping Organs with Forceps in Dissection Procedure of Laparoscopic Surgery

Author

Ebina, Koki, Abe, Takashige, Komizunai, Shunsuke, Tsujita, Teppei, Sase, Kazuya, Chen, Xiaoshuai, Higuchi, Madoka, Furumido, Jun, Iwahara, Naoya, Kurashima, Yo, Shinohara, Nobuo, Konno, Atsushi, Serafini, Paolo, Managing Editor, Guazzelli, Elisabeth, Series Editor, Rammerstorfer, Franz G., Series Editor, Wall, Wolfgang A., Series Editor, Schrefler, Bernhard, Series Editor, Venture, Gentiane, editor, Solis, Jorge, editor, Takeda, Yukio, editor, and Konno, Atsushi, editor

Published
2021
Full Text
View/download PDF

40. Correction to: Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2

Author

Tozawa, Akiko, Kimura, Fuminori, Takai, Yasushi, Nakajima, Takeshi, Ushijima, Kimio, Kobayashi, Hiroaki, Satoh, Toyomi, Harada, Miyuki, Sugimoto, Kohei, Saji, Shigehira, Shimizu, Chikako, Akiyama, Kyoko, Bando, Hiroko, Kuwahara, Akira, Furui, Tatsuro, Okada, Hiroshi, Kawai, Koji, Shinohara, Nobuo, Nagao, Koichi, Kitajima, Michio, Suenobu, Souichi, Soejima, Toshinori, Miyachi, Mitsuru, Miyoshi, Yoko, Yoneda, Akihiro, Horie, Akihito, Ishida, Yasushi, Usui, Noriko, Kanda, Yoshinobu, Fujii, Nobuharu, Endo, Makoto, Nakayama, Robert, Hoshi, Manabu, Yonemoto, Tsukasa, Kiyotani, Chikako, Okita, Natsuko, Baba, Eishi, Muto, Manabu, Kikuchi, Iwaho, Morishige, Ken-ichirou, Tsugawa, Koichiro, Nishiyama, Hiroyuki, Hosoi, Hajime, Tanimoto, Mitsune, Kawai, Akira, Sugiyama, Kazuhiko, Boku, Narikazu, Yonemura, Masato, Hayashi, Naoko, Aoki, Daisuke, Suzuki, Nao, and Osuga, Yutaka

Published
2022
Full Text
View/download PDF

43. Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment

Author

Minami, Keita, Osawa, Takahiro, Kojima, Takahiro, Hara, Tomohiko, Eto, Masatoshi, Takeuchi, Ario, Nakai, Yasutomo, Ueda, Kosuke, Ozawa, Michinobu, Uemura, Motohide, Ohba, Kojiro, Tamura, Keita, Shindo, Tetsuya, Nakagomi, Hiroshi, Takahashi, Atsushi, Anai, Satoshi, Yokomizo, Akira, Morizane, Shuichi, Kimura, Takahiro, Shimazui, Toru, Miyauchi, Yasuyuki, Mitsuzuka, Koji, Hara, Hiroaki, Yoshimura, Koji, Shiina, Hiroaki, Ito, Youichi M, Murai, Sachiyo, Nishiyama, Hiroyuki, Shinohara, Nobuo, and Kitamura, Hiroshi

Published
2023
Full Text
View/download PDF

45. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Author

Park, Se Hoon, van der Heijden, Michiel S., Necchi, Andrea, Castellano, Daniel, Bamias, Aristotelis, Lee, Jae Lyun, De Giorgi, Ugo, Bögemann, Martin, Eigl, Bernhard J., Tsiatas, Marinos, Powles, Thomas, Novikov, Andrey, Skoneczna, Iwona, Mukherjee, Som D., Suarez, Cristina, Westgeest, Hans, Fradet, Yves, Flechon, Aude, Ou, Yen-Chuan, Park, Inkeun, Matveev, Vsevolod, Pérez-Valderrama, Begoña, Cheng, Susanna, Frank, Stephen, Gurney, Howard, Anido, Urbano, Hamzaj, Alketa, Retz, Margitta, Sridhar, Srikala, Scagliotti, Giorgio Vittorio, Voortman, Jens, Alekseev, Boris, Alyasova, Anna, Komyakov, Boris, Dumez, Herlinde, Pavic, Michel, Kimura, Go, Mizokami, Atsushi, Osanto, Susanne, Arranz, Jose Angel, Piersma, Djura, Shin, Sang Joon, Karyakin, Oleg, Delgado, Ignacio, Gonzalez, Jose Luis, Pang, See-Tong, Tran, Anna, Lipatov, Oleg, Su, Wen-Pin, Flaig, Thomas, Alva, Ajjai, Park Kyong, Hwa, Kopyltsov, Evgeny, Almagro, Elena, Domenech, Monserrat, Chang, Yen-Hwa, Sautois, Brieuc, Ravaux, Andre, Aravantinos, Gerasimos, Georgoulias, Vasileios, Mulder, Sasja, Kim, Yu Jung, Kater, Fabio, Chevreau, Christine, Tagawa, Scott, Zalewski, Pawel, Joly, Florence, Loriot, Yohann, Hatiboglu, Gencay, Gianni, Luca, Morelli, Franco, Tambaro, Rosa, Hashimoto, Yasuhiro, Nosov, Alexander, Font, Albert, Rodriguez-Vida, Alejo M., Jones, Robert, Vasudev, Naveen, Srinivas, Sandhya, Zhang, Jingsong, Gil, Thierry, Finch, Daygen, Grimm, Marc-Oliver, Su, Yu-Li, Chowdhury, Simon, Hocking, Christopher, Plas, Eugen, North, Scott, Jensen, Niels Viggo, Theodore, Christine, Imkamp, Florian, Peer, Avivit, Kobayashi, Takashi, Sakai, Hideki, Sassa, Naoto, Yoshimura, Kazuhiro, Aarts, Maureen, Ferreira Castro, Ana, Topuzov, Marlen, Rodriguez, Juan Francisco, Vazquez, Federico Jose, Tsai, Yu-Chieh, Crabb, Simon, Hussain, Syed, Bendell, Johanna, Gross-Goupil, Marine, Gwenaelle, Gravis, Berger, Raanan, Statsenko, Galina, Evans, Linda, Drakaki, Alexandra, Somer, Bradley, Davis, Ian, Lynam, James, Borges, Giuliano, Dettino, Aldo, Fay, André P., Martins, Graziella, Zucca, Luis Eduardo, Agerbaek, Mads, Kalofonos, Haralambos, Rosenbaum, Eli, Enokida, Hideki, Kikukawa, Hiroaki, Nishimura, Kazuo, Tamada, Satoshi, Uemura, Motohide, Lopez, Yamil, Gietema, Jourik, Slojewski, Marcin, Fernandes, Isabel, Smolin, Alexey, Mazhar, Danish, Kalebasty, Arash Rezazadeh, Carthon, Bradley, Loidl, Wolfgang, Franke, Fabio, Girotto, Gustavo, Alimohamed, Nimira, Macfarlane, Robyn, Pappot, Helle, Niegisch, Guenter, Mavroudis, Dimitrios, Sella, Avishay, Porta, Camillo, Ebara, Shin, Nakamura, Motonobu, Obara, Wataru, Okuno, Norihiko, Shinohara, Nobuo, Sugimoto, Mikio, Suzuki, Akitaka, Tokuda, Noriaki, Uemura, Hiroji, Yamaguchi, Akito, Ramirez, Francisco, Rozanowski, Pawel, Wiechno, Pawel, Keam, Bhumsuk, Kislov, Nikolay, Plaksin, Denis, Cicin, Irfan, Kumar, Satish, Galsky, Matthew D., Petrylak, Daniel P., Rosales, Joseph, Vaishampayan, Ulka, Culine, Stephane, Papandreou, Christos, Nara, Taketoshi, Erman, Mustafa, Kreiger, Laurence, Janoski, Juliana, Rosa, Diogo, Siqueira, Mariana, Canil, Christina, Sengelov, Lisa, Tourani, Jean-Marc, Arai, Gaku, Hashine, Katsuyoshi, Kawakita, Mutsushi, Nakaigawa, Noboru, Nomi, Hayahito, Shiina, Hiroaki, Suzuki, Hiroyoshi, Yonese, Junji, Kuri, Roberto, Macedo, Eleazar, Rivera, Samuel, Villalobos Prieto, Alberto, Polakiewicz-Gilowska, Anna, Zaucha, Renata, Lopes, Fabio, Ponomarev, Roman, Pomerantz, Mark, Shariat, Shahrokh, Luk, Cynthia, Lesniewski-Kmak, Krzysztof, van der Heijden, Michiel S, Galsky, Matthew D, Petrylak, Daniel P, Ogawa, Osamu, Lee, Jae-Lyun, Eigl, Bernhard J, Mukherjee, Som D, Suárez, Cristina, Fay, André P, Duran, Ignacio, Wildsmith, Sophie, He, Philip, Angra, Natasha, Gupta, Ashok K, Levin, Wendy, and Bellmunt, Joaquim

Published
2020
Full Text
View/download PDF

46. Gap analysis between trainees' subjective competencies and the competencies expected by instructors in urology: A need assessment survey in Japan.

Author

Hori, Kanta, Abe, Takashige, Abe, Noriyuki, Abe, Junya, Okada, Kazufumi, Takahashi, Keita, Harada, Shigeru, Furumido, Jun, Murai, Sachiyo, Kon, Masafumi, Hashimoto, Kohei, Masumori, Naoya, Kakizaki, Hidehiro, and Shinohara, Nobuo

Subjects
NEEDS assessment, PLASTIC surgery, UROLOGY, OPERATIVE surgery, DELPHI method, UROLOGICAL surgery, FORMATIVE tests
Abstract

Objective: According to the rapid progress in surgical techniques, a growing number of procedures should be learned during postgraduate training periods. This study aimed to clarify the current situation regarding urological surgical training and identify the perception gap between trainees' competency and the competency expected by instructors in Japan. Methods: Regarding the 40 urological surgical procedures selected via the Delphi method, we collected data on previous caseloads, current subjective autonomy, and confidence for future skill acquisition from trainees (<15 post‐graduate years [PGY]), and the competencies when trainees became attending doctors expected by instructors (>15 PGY), according to a 5‐point Likert scale. In total, 174 urologists in Hokkaido Prefecture, Japan were enrolled in this study. Results: The response rate was 96% (165/174). In a large proportion of the procedures, caseloads grew with accumulation of years of clinical practice. However, trainees had limited caseloads of robotic and reconstructive surgeries even after 15 PGY. Trainees showed low subjective competencies at present and low confidence for future skill acquisition in several procedures, such as open cystectomy, ureteroureterostomy, and ureterocystostomy, while instructors expected trainees to be able to perform these procedures independently when they became attending doctors. Conclusion: Trainees showed low subjective competencies and low confidence for future skill acquisition in several open and reconstructive procedures, while instructors considered that these procedures should be independently performable by attending doctors. We believe that knowledge of these perception gaps is helpful to develop a practical training program. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Cross‐sectional study of therapy‐related expectations/concerns of patients with metastatic renal cell carcinoma and physicians in Japan.

Author

Kimura, Go, Fujii, Yasuhisa, Osawa, Takahiro, Uchitomi, Yosuke, Honda, Kazunori, Kondo, Miki, Otani, Ariko, Wako, Tetsuya, Kawai, Daisuke, Mitsuda, Yoshihide, Sakashita, Naotaka, and Shinohara, Nobuo

Subjects
RENAL cell carcinoma, PHYSICIANS, CROSS-sectional method, JAPANESE people, PATIENTS' attitudes
Abstract

Objective: To achieve patient‐centricity in metastatic renal cell carcinoma (mRCC) treatment, it is essential to clarify the differences in perspectives between patients and physicians. This cross‐sectional analysis of a web survey aimed to clarify the differences in expectations and concerns between mRCC patients and physicians regarding systemic mRCC therapy in Japan. Methods: Surveys from 83 patients and 165 physicians were analyzed. Results: The top three most significant differences in expectations of systemic therapy between patients and physicians (patient‐based physician value) were "Chance of achieving treatment‐free status" (−30.1%, p < 0.001), "Longer survival" (+25.8%, p < 0.001), and "Chance of eliminating all evidence of disease" (−25.6%, p < 0.001). The top three most significant differences in concerns for systemic therapy between patients and physicians (patient‐based physician value) were "Lack of efficacy" (+36.1%, p < 0.001), "Lack of knowledge of treatment" (−28.2%, p < 0.001), and "Daily activities affected by side effects" (+22.3%, p < 0.001). Diarrhea, fatigue/malaise, and nausea/vomiting were patients' most distressing adverse events; 50.6% of patients had difficulty telling their physicians about adverse events such as fatigue, anxiety, and depression. Conclusions: This study demonstrated a gap between patients with mRCC and physicians in their expectations and concerns for systemic therapy. Japanese patients with mRCC suffer from a number of adverse events, some of which are not shared with physicians. This study highlights the importance of communicating well with patients in clinical practice to achieve patient‐centricity in systemic treatment for mRCC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Financial Toxicity in Japanese Patients with Metastatic Renal Cell Carcinoma: A Cross-Sectional Study.

Author

Kimura, Go, Fujii, Yasuhisa, Honda, Kazunori, Osawa, Takahiro, Uchitomi, Yosuke, Kondo, Miki, Otani, Ariko, Wako, Tetsuya, Kawai, Daisuke, Mitsuda, Yoshihide, Sakashita, Naotaka, and Shinohara, Nobuo

Subjects
CROSS-sectional method, PEARSON correlation (Statistics), RESEARCH funding, MULTIVARIATE analysis, FINANCIAL stress, METASTASIS, SURVEYS, RENAL cell carcinoma, QUALITY of life, STATISTICS
Abstract

Simple Summary: We investigated financial toxicity in Japanese patients with metastatic renal cell carcinoma using the COST tool. Despite universal coverage, patients in Japan had similar levels of financial toxicity as in other countries. There was a positive correlation between the FACT-G total score and the COST score. Age < 65 years and not having private health insurance were associated with higher financial toxicity. Information on the financial toxicity experienced by Japanese patients with metastatic renal cell carcinoma (mRCC) is lacking, even though Japan has its own unique public health insurance system. Thus, a web-based survey was conducted to evaluate the financial toxicity experienced by Japanese mRCC patients using the COmprehensive Score for financial Toxicity (COST) tool. This study enrolled Japanese patients who underwent, or were undergoing, systemic therapy for mRCC. The outcomes evaluated were the distribution of COST scores, the correlation between COST and quality of life (QOL) assessed by the Functional Assessment of Cancer Therapy-General (FACT-G) scale, and demographic factors associated with financial toxicity. The median (range) COST score was 19.0 (3.0–36.0). The Pearson correlation coefficient for COST and FACT-G total scores was 0.40. Univariate analysis revealed that not having private health insurance and lower household income per year were significantly associated with lower COST scores. Multivariate analyses showed that age < 65 years and not having private health insurance were significantly associated with lower COST scores. This study revealed that Japanese mRCC patients experience adverse financial impacts even under the universal health insurance coverage system available in Japan, and financial toxicity negatively affects their QOL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Longitudinal mortality risks and kidney functional outcomes in Japanese living kidney donors.

Author

Hirose, Takayuki, Hotta, Kiyohiko, Osawa, Takahiro, Yokota, Isao, Inao, Tasuku, Tanabe, Tatsu, Iwahara, Naoya, and Shinohara, Nobuo

Subjects
KIDNEY physiology, KIDNEYS, MORTALITY, KIDNEY failure, GLOMERULAR filtration rate
Abstract

Objectives: Previous studies suggested that living kidney donors do not have a higher risk of death or kidney failure than the general population. However, living kidney donor risk is controversial. Furthermore, only a few studies have evaluated long‐term kidney function after kidney donation. Methods: This study evaluated Japanese kidney donor' long‐term outcomes, including mortality and kidney function. From 1965 to 2015, 230 donors (76 males, 154 females, and a median age of 54) were enrolled in this study. The median observation period was 11.0 (range, 0.3–41.0) years. Results: In total, 215 donors were still alive, and 15 had died. Causes of death included malignancies, cardiovascular disease, pneumonia, suicide, gastrointestinal bleeding, and kidney failure. Actual donor survival rates at 10, 20, and 30 years were 95.3%, 90.7%, and 80.9%, respectively. These values were comparable to age‐ and gender‐matched expected survival. Long‐term kidney function after donation was evaluated in 211 donors with serum creatinine data. Two donors developed kidney failure 24 and 26 years post‐donation, respectively. The percentage of donors whose estimated glomerular filtration rate (eGFR) remained ≥45 mL/min/1.73 m2 at 10, 20, and 30 years after donation were 84.2%, 73.0%, and 63.9%, respectively. Survival rates of donors with eGFR <45 mL/min/1.73 m2 were comparable to those in persons with eGFR >45 mL/min/1.73 m2. Conclusion: Our findings revealed that kidney donors did not have a higher long‐term risk of death than the general population. Although some donors showed decreased kidney function after donation, kidney function did not impact their survival. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Systematic molecular analyses for 115 karyotypically normal men with isolated non-obstructive azoospermia.

Author

Muranishi, Yuki, Kobori, Yoshitomo, Katoh-Fukui, Yuko, Tamaoka, Satoshi, Hattori, Atsushi, Osaka, Akiyoshi, Okada, Hiroshi, Nakabayashi, Kazuhiko, Hata, Kenichiro, Kawai, Tomoko, Ogata-Kawata, Hiroko, Iwahata, Toshiyuki, Saito, Kazuki, Kon, Masafumi, Shinohara, Nobuo, and Fukami, Maki

Subjects
AZOOSPERMIA, JAPANESE people, ACADEMIC medical centers, MOLECULAR diagnosis, GENETIC variation, MALE infertility
Abstract

STUDY QUESTION Do copy-number variations (CNVs) in the azoospermia factor (AZF) regions and monogenic mutations play a major role in the development of isolated (non-syndromic) non-obstructive azoospermia (NOA) in Japanese men with a normal 46, XY karyotype? SUMMARY ANSWER Deleterious CNVs in the AZF regions and damaging sequence variants in eight genes likely constitute at least 8% and approximately 8% of the genetic causes, respectively, while variants in other genes play only a minor role. WHAT IS KNOWN ALREADY Sex chromosomal abnormalities, AZF-linked microdeletions, and monogenic mutations have been implicated in isolated NOA. More than 160 genes have been reported as causative/susceptibility/candidate genes for NOA. STUDY DESIGN, SIZE, DURATION Systematic molecular analyses were conducted for 115 patients with isolated NOA and a normal 46, XY karyotype, who visited our hospital between 2017 and 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS We studied 115 unrelated Japanese patients. AZF-linked CNVs were examined using sequence-tagged PCR and multiplex ligation-dependent probe amplification, and nucleotide variants were screened using whole exome sequencing (WES). An optimized sequence kernel association test (SKAT-O), a gene-based association study using WES data, was performed to identify novel disease-associated genes in the genome. The results were compared to those of previous studies and our in-house control data. MAIN RESULTS AND THE ROLE OF CHANCE Thirteen types of AZF-linked CNVs, including the hitherto unreported gr/gr triplication and partial AZFb deletion, were identified in 63 (54.8%) cases. When the gr/gr deletion, a common polymorphism in Japan, was excluded from data analyses, the total frequency of CNVs was 23/75 (30.7%). This frequency is higher than that of the reference data in Japan and China (11.1% and 14.7%, respectively). Known NOA-causative AZF-linked CNVs were found in nine (7.8%) cases. Rare damaging variants in known causative genes (DMRT1 , PLK4 , SYCP2, TEX11 , and USP26) and hemizygous/multiple-heterozygous damaging variants in known spermatogenesis-associated genes (TAF7L , DNAH2 , and DNAH17) were identified in nine cases (7.8% in total). Some patients carried rare damaging variants in multiple genes. SKAT-O detected no genes whose rare damaging variants were significantly accumulated in the patient group. LIMITATIONS, REASONS FOR CAUTION The number of participants was relatively small, and the clinical information of each patient was fragmentary. Moreover, the pathogenicity of identified variants was assessed only by in silico analyses. WIDER IMPLICATIONS OF THE FINDINGS This study showed that various AZF-linked CNVs are present in more than half of Japanese NOA patients. These results broadened the structural variations of AZF-linked CNVs, which should be considered for the molecular diagnosis of spermatogenic failure. Furthermore, the results of this study highlight the etiological heterogeneity and possible oligogenicity of isolated NOA. STUDY FUNDING/COMPETING INTEREST(S) This study was supported by Grants from the Japan Society for the Promotion of Science (21K19283 and 21H0246), the Japan Agency for Medical Research and Development (22ek0109464h0003), the National Center for Child Health and Development, the Canon Foundation, the Japan Endocrine Society, and the Takeda Science Foundation. The results of this study were based on samples and patient data obtained from the International Center for Reproductive Medicine, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan. The authors have no conflicts of interest to disclose. TRIAL REGISTRATION NUMBER N/A. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results